The 2025 Tech Power Players in the sustainability sector
Strazik sees opportunities to bring the best ideas of clean-tech startups into mass production and get their inventions into the hands of big customers.
Advertisement
'We're in a better position to play offense than we were even 12 months ago,' Strazik says. 'Now we're in a position of strength.'
Strazik, 46, led
Vernova specializes in three lines of business: power generation (natural gas, steam, and nuclear); wind turbines; and electrification (primarily grid infrastructure such as transformers and circuit breakers). Revenues are expected to reach as high as $37 billion this year and grow to $45 billion in 2028.
Vernova sustained a setback last summer when a blade for the Vineyard Wind offshore project broke apart and debris washed up on nearby beaches. The company is working with the wind farm developer to replace blades at the site and complete the project.
Advertisement
Investors are bullish on Vernova because electricity demand is forecast to grow. Tech companies will need more and bigger data centers to advance artificial intelligence. Consumers will use more power for electric vehicles, heat pumps, and induction stoves. Governments and companies will rely on electricity to move closer to net-zero carbon goals.
In Canada, for example, Vernova is building the next generation of smaller, safer nuclear reactors. At Vernova labs in Niskayuna, New York, scientists are working on technologies to capture carbon emissions from power generators.
'It's very easy to get up in the morning and very clearly see the impact that our work can have,' Strazik says. 'It just feels like our time. That's a privilege but it's one we need to manage carefully.'
More tech power players to watch in the sustainability sector:
Explore more sectors
Jon Chesto can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
We recently published . Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development. In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech. The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities. Copyright: dolgachov / 123RF Stock Photo Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s oncology pipeline has broadened, with several candidates expected to advance into human studies. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
MIT Student Drops Out Because She Says AGI Will Kill Everyone Before She Can Graduate
We're all probably feeling a little anxious about AI. It's horrible for the environment, is used as an excuse to fire workers, floods the internet with misinformation and slop, entrenches government surveillance, and appears to be driving people into psychosis. And so, at a time when many college students are dropping out to join AI startups, one former MIT student says she called it quits because she's afraid of something altogether more catastrophic: that an artificial general intelligence (AGI), or superhuman AI, will completely wipe out the human race, Forbes reports. "I was concerned I might not be alive to graduate because of AGI," Alice Blair, who enrolled at the university in 2023, told the publication. "I think in a large majority of the scenarios, because of the way we are working towards AGI, we get human extinction." Blair now works as a technical writer at the nonprofit Center for AI Safety, and has no plans to go back to MIT. She joined, hoping to meet other people interested in making AI safe, and apparently was disappointed. "I predict that my future lies out in the real world," she told Forbes. Nikola Jurković, a Harvard alum who served at his school's AI safety club, is sympathetic to the idea. "If your career is about to be automated by the end of the decade, then every year spent in college is one year subtracted from your short career," he told Forbes. "I personally think AGI is maybe four years away and full automation of the economy is maybe five or six years away." Building an AGI, a system that matches or surpasses human intelligence, is much of the AI industry's endgame. OpenAI CEO Sam Altman called the recent launch of its poorly-received AI model GPT-5 a major stepping stone towards AGI, even going as far as to call it "generally intelligent." Many experts are skeptical, however, that we're anywhere near building such a powerful AI model, and point to recent signs that improvements to the tech are hitting a wall. "It is extremely unlikely that AGI will come in the next five years," Gary Marcus, an AI researcher and outspoken critic of the industry, told Forbes. "It's just marketing hype to pretend otherwise when so many core problems (like hallucinations and reasoning errors) remain unsolved." And while there are very real forms of harm that AI can cause, outright extinction is a little far-fetched, Marcus said. In fact, the AI industry probably wants you to buy into AI doomsday prophesying. Altman and other tech CEOs raise these risks themselves. Doing so creates the impression that the tech is far more capable than it currently is, and allows these companies to control the narrative around how the tech should be regulated. And if you're envisioning an apocalypse like in "The Matrix" movies — human enslavement at the hands of machine intelligences that rebelled against their creators — you may be ignoring the very mundane forms of harm it's already causing, like job automation and the gutting of the environment. More on AI: Sam Altman Calls His Own AI Model "Annoying" After Being Forced to Raise It From the Dead Solve the daily Crossword
Yahoo
2 days ago
- Yahoo
Rivian's CEO explains why he got a Ph.D. — and why he chose MIT over Stanford
Rivian CEO RJ Scaringe said that his Ph.D. from MIT gave him "credibility" when approaching investors. Scaringe told the "Tosh Show" that he went to Stanford for a day before switching over to MIT for their automotive program. "It was like being recruited for a nerd sports team," Scaringe said of choosing between MIT and Stanford. Some people pursue Ph.D.s to work in academia or to attain lofty research positions. The CEO of Rivian got his so people would take him seriously. RJ Scaringe founded Mainstream Motors — later renamed Rivian — in 2009. It took over a decade to collect capital, build manufacturing capabilities, and eventually distribute the company's first consumer electric vehicle, the R1T. When pitching his EV company to investors, Scaringe had a résumé perk: his Ph.D. from Massachusetts Institute of Technology. On the "Tosh Show," Scaringe said that he figured the degree would put him in good standing in investor rooms. "I thought, 'I'll need a lot of money. I don't have any money, and if I'm going to get other people to invest money into this thing that I want to build, me having a Ph.D. from MIT or equivalent makes that more likely,'" Scaringe said. Pitching a vehicle company is difficult, as Scaringe described on the podcast. Given the upfront capital costs to make a basic prototype, EV entrepreneurs like Scaringe are often pitching an idea more than a discreet product. Thus, EV founders need credibility — and Scaringe didn't want to wait decades. "I didn't want to go work at a car company for 20 years and earn credibility," he said. "So I wanted to get like credibility as quickly as I could." For Scaringe, that came in the form of a Ph.D. in automotive mechanical engineering. MIT is a hotbed for entrepreneurs. Notable Ph.D. alums include Intel cofounder Robert Noyce and Boston Dynamics founder Marc Raibert. Amar Bose of Bose Corporation got his Sc.D. from the institution. When picking his graduate institution, Scaringe had two options: MIT or Stanford University. Having graduated first in his class at Rensselaer Polytechnic Institute, Scaringe said he had plenty of options and was being courted by various programs. "It was like being recruited for a nerd sports team because MIT offered me this amazing role, Stanford offered me this amazing role," he said. Scaringe accepted his offer from Stanford and enrolled for a day before switching over to MIT. "I actually preferred the program at MIT," Scaringe said. "The reason I really liked what MIT had is that they had an automotive-specific program and a lab built around automotive, and I knew I wanted to start what eventually became Rivian." Scaringe called his reasoning for getting a Ph.D. "wonderfully naive" — but "it worked." Read the original article on Business Insider Sign in to access your portfolio
